[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351256-105":59,"doc-detail-351256-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","multifunctional-bismuth-nanoplatforms-augment-radioactive-iodine-therapy-in-anaplastic-thyroid-cancer","Multifunctional Bismuth Nanoplatforms Augment Radioactive Iodine Therapy in Anaplastic Thyroid Cancer","","Multifunctional bismuth nanoplatforms are investigated to augment radioactive iodine (RAI) therapy for anaplastic thyroid cancer (ATC), addressing two key limits of conventional treatment: low intrinsic energy of 131I and loss of sodium/iodine symporter (NIS) function after dedifferentiation. The study combines nanomaterial-mediated radiosensitization—via secondary electron generation, hydrolysis, and ROS enhancement—with drug-driven redifferentiation to restore iodine uptake. A Bi@Digoxin formulation is characterized and evaluated through in vitro and in vivo experiments, demonstrating triple synergistic antitumor effects including NIR-triggered controlled release and photothermal ablation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multifunctional-bismuth-nanoplatforms-augment-radioactive-iodine-therapy-in-anaplastic-thyroid-cancer/351256/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multifunctional-bismuth-nanoplatforms-augment-radioactive-iodine-therapy-in-anaplastic-thyroid-cancer/351256.png","ImageObject",300,407,{"name":92,"@type":93},"Mia  ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What main problem limits radioactive iodine therapy in anaplastic thyroid cancer?","Question",{"text":113,"@type":114},"ATC often loses sodium/iodine symporter (NIS) function due to dedifferentiation, which makes tumors resistant to RAI. The intrinsic low energy of 131I further reduces tumor eradication efficacy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What are the two RAI-sensitizing strategies used in this study?",{"text":118,"@type":114},"First, metallic nanomaterials generate secondary electrons that promote hydrolysis and increase reactive oxygen species (ROS). Second, a drug approach reverses the dedifferentiated phenotype to restore tumor iodine uptake.",{"name":120,"@type":111,"acceptedAnswer":121},"How does Bi@Digoxin enhance the efficacy of RAI against ATC?",{"text":122,"@type":114},"Bi@Digoxin restores NIS function to counter RAI resistance, uses bismuth’s high atomic number to increase radiation energy deposition and drive ROS bursts and DNA double-strand breaks, and combines NIR-triggered controlled drug release with photothermal ablation to inhibit tumor growth.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},351256,1790226611,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","International Journal of Nanomedicine  \n Open Access Full Text Article  \nORIGINAL RESEARCH  \nMultifunctional Bismuth Nanoplatforms Augment Radioactive Iodine Therapy in Anaplastic Thyroid Cancer  \nXijie Qu 1 , 2 , *, Tong Liu 3 , *, Yu Wang2 ,4 , Xinyuan Wei2 ,4 , Ye Yang 1 , Liya Gu 1 , Kun Yang 2 , Jing Zhang 1 , Yan Liu 1 , Yiqian Liang 1 , Yanzhen Zheng2 ,4 , Aimin Yang 1 , 2  \n1Department of Nuclear Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, 710061, People’s Republic of China; 2School of Future Technology, Xi’an Jiaotong University, Xi’an, Shaanxi, 710061, People’s Republic of China; 3Department of Surgical Intensive Care Unit, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, 710061, People’s Republic of China; 4Frontier Institute of Science and Technology, Xi’an Jiaotong University, Xi’an, Shaanxi, 710054, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Aimin Yang, Department of Nuclear Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, 277 West Yanta Road, Xi’an, Shaanxi, 710061, People’s Republic of China, [Email yangaimin@mail.xjtu.edu.cn](Email yangaimin@mail.xjtu.edu.cn); Yanzhen Zheng, Frontier Institute of Science and Technology, Xi’an Jiaotong University, 99 Yanxiang Road, Xi’an, Shaanxi, 710054, People’s Republic of China, Email [zheng.yanzhen@xjtu.edu.cn](zheng.yanzhen@xjtu.edu.cn)  \n\n| Introduction: Radioactive iodine (RAI) therapy is a highly specific targeted treatment for thyroid cancer. However, the intrinsic low energy of 131I limits its efficacy in tumor eradication. Additionally, certain thyroid cancers exhibit a loss of sodium/iodine symporter (NIS) function due to severe dedifferentiation, compromising the therapeutic effectiveness of RAI.\u003Cbr>Methods: Our work was based on two distinct RAI-sensitizing strategies: (1) the generation of secondary electrons by irradiated metallic nanomaterials to promote hydrolysis and enhance reactive oxygen species (ROS) production, and (2) drug-induced reversal of the dedifferentiated phenotype of tumor cells to restore iodine uptake. Accordingly, we developed a multifunctional nanoplatform, termed Bi@Digoxin, by loading digoxin onto bismuth nanoparticles (BiNPs) . The physicochemical properties of Bi@Digoxin were systematically characterized. Furthermore, its therapeutic efficacy was rigorously evaluated through in vitro and in vivo experiments, demonstrating significant treatment outcomes.\u003Cbr>Results: The experiments demonstrate that Bi@Digoxin enhances the efficacy of RAI in Anaplastic thyroid cancer (ATC) through a triple synergistic mechanism: utilizing nanocarriers for efficient delivery of Digoxin to restore NIS function in tumor cells, reversing RAI resistance in ATC; leveraging the high atomic number property of bismuth (Bi) to enhance radiation energy deposition, promoting ROS bursts and DNA double-strand breaks; and combining near-infrared (NIR) laser-triggered controlled drug release with photothermal ablation to significantly inhibit tumor growth.\u003Cbr>Conclusion: Bi@Digoxin significantly enhances the therapeutic efficacy of RAI, offering a novel synergistic treatment strategy for ATC that combines biosafety and scalable production, with significant potential for clinical translation.\u003Cbr>Keywords: radioactive iodine, redifferentiation, radiosensitization, photothermal therapy |\n| --- |\n| Introduction\u003Cbr>Anaplastic thyroid cancer (ATC) represents a rare yet highly malignant subtype of thyroid carcinoma, characterized by a particularly poor prognosis.1 Predominantly affecting elderly individuals, ATC exhibits a higher prevalence in female patients.2 The median overall survival (OS) for individuals diagnosed with ATC is approximately 5 months, with a one-year OS rate of 20% and a disease-specific mortality rate approaching 100% .3 The aggressive nature of ATC often results in its diagnosis at an advanced, inoperable stage, whe","cbCair5JXYfN5VZR","https://ap.wps.com/l/cbCair5JXYfN5VZR","pdf",11233234,15,"English","# Introduction\n## Radioactive iodine therapy and its limitations in ATC\n# Methods\n## RAI-sensitizing strategies and Bi@Digoxin design\n# Results\n## Triple synergistic mechanism and therapeutic outcomes\n# Conclusion","[{\"question\":\"What main problem limits radioactive iodine therapy in anaplastic thyroid cancer?\",\"answer\":\"ATC often loses sodium/iodine symporter (NIS) function due to dedifferentiation, which makes tumors resistant to RAI. The intrinsic low energy of 131I further reduces tumor eradication efficacy.\"},{\"question\":\"What are the two RAI-sensitizing strategies used in this study?\",\"answer\":\"First, metallic nanomaterials generate secondary electrons that promote hydrolysis and increase reactive oxygen species (ROS). Second, a drug approach reverses the dedifferentiated phenotype to restore tumor iodine uptake.\"},{\"question\":\"How does Bi@Digoxin enhance the efficacy of RAI against ATC?\",\"answer\":\"Bi@Digoxin restores NIS function to counter RAI resistance, uses bismuth’s high atomic number to increase radiation energy deposition and drive ROS bursts and DNA double-strand breaks, and combines NIR-triggered controlled drug release with photothermal ablation to inhibit tumor growth.\"}]","Multifunctional Bismuth Nanoplatforms Augment Radioactive Iodine Therapy in Anaplastic Thyroid Cancer | PDF",1790093243,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94a7518c23f9c881783e6f23800200e3.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe0d268aa034e0cde76b5ed79dc7a0f2.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a57d84084da860b2cc2bec356a7f194.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d11f4513ccf12a9f5cf60e1d6797d27d.webp",980,1268]